Q-omics provides the consensus-scored FOXM1 profile across patient tissues and cancer cell-line models. FOXM1 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FOXM1 is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, FOXM1 RNA expression shows 26,327 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, BLCA, and LUAD as cancer lineages where FOXM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXM1 survival associations across molecular data types. FOXM1 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXM1 RNA expression–survival associations across cancer types. High FOXM1 expression shows unfavorable associations in ACC, KIRP, KIRC, MESO, LIHC and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FOXM1 RNA expression.
This table summarizes FOXM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FOXM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXM1 shows higher tumor expression in BLCA, HNSC, KIRC, LUAD, KIRP and COAD. The BLCA box plot shows higher FOXM1 RNA expression in tumor versus normal tissue (log2 FC = +3.395, t-test p < 0.001).
This table shows molecular features associated with FOXM1 in patient tissues and cancer cell lines. In patient samples, FOXM1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
